Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy

A technology of tenascin-c and prognosis assessment, which is applied in disease diagnosis, material inspection products, measuring devices, etc., can solve the problems of lack of research on the role of Tenascin-C, and achieve the effect of assisting prognosis assessment

Active Publication Date: 2018-12-11
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far, there is still a lack of research on the role of Tenascin-C in kidney diseases. Based on the current state of the art, the inventors of the present application intend to try to find good biomarkers for clinical application to assist in the diagnosis and prognosis of IgA nephropathy. , especially to provide urine Tenascin-C ratio creatinine (uTNC / Cr) as a biomarker for the preparation of preparations for diagnosis and prognosis evaluation of idiopathic IgA nephropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy
  • Application of urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy
  • Application of urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1 normal person, IgA nephropathy patient's serum, the basic distribution experiment of urine Tenascin-C

[0016] Serum TNC 22.01 (16.83-38.61) ng / ml and urine TNC / creatinine 49.68 (40.65-60.70) ug / g were used in 6 normal people; and serum TNC 235.56 (165.21-295.90) ​​in 134 patients with idiopathic IgA nephropathy ng / ml, urine TNC / creatinine 101.27 (54.32 ~ 250.02) ug / g test, the results show that serum and urine TNC levels in patients with IgA nephropathy are higher than normal (such as figure 1 shown).

Embodiment 2I

[0017] Example 2 Correlation Experimental Study of Serum and Urinary Tenascin-C in IgA Nephropathy

[0018] After the relevant serum and urine TNC described in embodiment 1 were carried out with 10 as the logarithmic transformation, the normal distribution characteristics of continuous variables were met through the Kolmogorov-Smirnov test, and the research population lg (sTNC), lg (uTNC / Cr ) to perform Pearson correlation analysis, calculate Pearson correlation coefficient r=0.03, P=0.729, that is, there is no significant correlation between serum and urinary TNC levels in patients with IgA nephropathy (such as figure 2 shown); based on the molecular weight of the TNC polypeptide chain of 220-330kDa, it is a macromolecular protein. Therefore, the results show that urinary TNC is not mainly produced by serum TNC through glomerular filtration, but by the pathological expression of renal tissue itself. urine out.

Embodiment 3

[0019] Example 3. Correlation analysis experiment of IgA nephropathy serum, urine Tenascin-C and clinical indicators

[0020] Based on the relevant serum and urine TNC described in Example 1, the bivariate Spearman correlation analysis was carried out to the research population sTNC, uTNC / Cr and various clinical indicators respectively, and the Spearman correlation coefficient r and significance P were calculated (as shown in Table 1 ), the results showed that sTNC was correlated with blood pressure, serum creatinine, eGFR EPI , albumin, 24-hour urine protein quantification, UACR and other clinical indicators reflecting the severity of IgA nephropathy had no significant correlation; while urinary Tenascin-C ratio creatinine (uTNC / Cr) was significantly negatively correlated with albumin and hemoglobin (P <0.001=, it is positively correlated with urinary RBC and urinary microalbumin / creatinine. It can also be inferred from clinical indicators that urinary Tenascin-C ratio creati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of molecular biological marker diagnosis and prognosis evaluation and relates to an application of a urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy. The urea Tenascin-C: creatinine (uTNC / Cr) as a marker can be used for diagnosing the severity of illness of the idiopathic IgA nephropathy andprognosis evaluation. By detecting the level of the urea Tenascin-C: creatinine, a result shows that the uTNC / Cr level of a patent with idiopathic IgA nephropathy is higher than that of a normal person, and the urea TNC is ejected along with urea after lesion expression of segment glomerular sclerosis, crescent in kidney tissues and the like. Meanwhile, the uTNC / Cr level can reflect the expressionquantity of TNC of glomerulus, reflect the severity of lesion of IgA nephropathy and can assist prognosis evaluation of the IgA nephropathy indirectly. The invention provides a preparation which is time-saving, high in sensitivity and accuracy, low in cost and efficient in diagnosing and prognosis evaluating idiopathic IgA nephropathy compared with prior art and a kit for the application.

Description

technical field [0001] The invention belongs to the field of molecular biological marker diagnosis and prognosis evaluation, and in particular relates to the use of urine Tenascin-C ratio creatinine in the preparation of idiopathic IgA nephropathy preparations for diagnosis and prognosis evaluation. The urine Tenascin-C ratio creatinine (uTNC / Cr) as a marker can be used to diagnose the disease severity and prognosis of idiopathic IgA nephropathy. Background technique [0002] The prior art discloses that IgA nephropathy (IgA nephropathy, IgAN) is the most common cause of glomerular hematuria in my country, and can occur at any age; the number of patients is large, the distribution is wide, and heterogeneity. According to the survey, 15-40% of patients with IgA nephropathy will progress to end-stage renal disease (ESRD) within 20-25 years after diagnosis. Studies have shown that the pathogenesis of IgA nephropathy is not yet fully understood, and there is strong heterogenei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/70
CPCG01N33/6893G01N33/70G01N2800/50G01N2800/347
Inventor 郝传明谢琼虹严敏骅刘少军
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com